All In Biotech

Drug Trial Radar · NCT07860554

Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer

A Phase II Study to Validate the Efficacy and Safety of Pluvicto in African American Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

88

Planned (sponsor's estimate)

Start

Nov 2, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Emory UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI); Novartis
First posted
Oct 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests how well Pluvicto works in treating African American patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that has continued to grow and spread despite the surgical removal of the testes or medical intervention to block androgen production (castration-resistant). Pluvicto is a targeted radioligand therapy. It works like a guided missile, combining tumor seeking molecules with a radioactive isotope. It circulates through the bloodstream, binds to a protein on prostate cancer cells called prostate specific membrane antigen, and destroys them using radiation. Pluvicto is approved by the Food and Drug Administration for the treatment of metastatic castration-resistant prostate cancer. This trial may help researchers determine the safety and efficacy of Pluvicto specifically in African American patients with metastatic castration-resistant prostate cancer.

Conditions

  • Metastatic Castration-Resistant Prostate Adenocarcinoma
  • Stage IVB Prostate Cancer AJCC v8

Interventions

  • Biopsy ProcedureProcedure

    Undergo biopsy

  • Biospecimen CollectionProcedure

    Undergo collection of blood samples

  • Bone ScanProcedure

    Undergo bone scan

  • Computed TomographyProcedure

    Undergo CT

  • Lutetium Lu 177 Vipivotide TetraxetanDrug

    Given IV

  • PSMA PET ScanProcedure

    Undergo PSMA PET scan

  • Questionnaire AdministrationOther

    Ancillary studies

  • Single Photon Emission Computed TomographyProcedure

    Undergo SPECT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic progression-free survival (rPFS)Time frame: From the start of study treatment to the first objective documentation of radiographic disease progression or death, assessed up to 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.